{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0072677\nAge: 67\nGender: Male\nSample ID: P-0072677-T02-IM7\nGene Panel: IMPACT505\nCancer Type: Lung Adenocarcinoma\nSample Type: Primary\nTumor Purity: 20.0%\n=============\nDNA Variants:\nARID1A c.376G>A (p.G126S) - in 5.00% of 436 reads\nASXL1 c.1259C>T (p.A420V) - in 8.00% of 462 reads\nEGFR c.2156G>C (p.G719A) - in 7.00% of 313 reads\nEGFR c.2303G>T (p.S768I) - in 11.00% of 372 reads\nELF3 c.822C>G (p.H274Q) - in 12.00% of 504 reads\nEZH1 c.1951G>A (p.E651K) - in 13.00% of 289 reads\nMAP3K1 c.3632A>G (p.E1211G) - in 8.00% of 345 reads\nTP53 c.818G>T (p.R273L) - in 6.00% of 400 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Lung Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Advanced or Metastatic\",\n    \"Drug Name\": \"Erlotinib\",\n    \"Prior Treatment or Resistance Status\": \"EGFR G719A and S768I mutations present; consider first-line EGFR TKI therapy\",\n    \"Genomic Features\": \"EGFR G719A and S768I mutations\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s004lbl.pdf\"\n  }\n}"
}